At each time point, the number at risk and the mean value include only patients who were receiving at least one vasopressor. Table 2 Primary and Secondary End Points. At 48 hours, improvement ...

We also systematically collected data regarding use of and adverse outcomes related to vasopressor use through central and peripheral venous catheters (Tables S17, S18, and S19). We found three ...

Vasopressors are a group of medicines that constrict (tighten) blood vessels and raise blood pressure. They’re used to treat severely low blood pressure, especially in people who are critically ...

2 Therefore, the Surviving Sepsis Campaign guideline recommends prioritizing treatment of low MAP through vasopressors given peripherally, rather than waiting for placement of a central venous ...

With this in mind, the recent VANISH trial [4] sought to determine whether AVP in higher than previously used doses (up to 0.06 U/min) would improve renal outcomes compared with norepinephrine ...

The overall rate of complication was 4.7%, and the rate of complication was 3.5% during the administration of peripheral vasopressors in the presence of the retrieval team. "The complication rate ...

However, they also found that the presence of gram-negative bacteria, excluding Pseudomonas, was a risk factor for worse outcomes including higher mortality, ICU admission and vasopressor use in ...

Another 3.7% had unknown mortality status. The data revealed that patients who received phenylephrine as the first vasopressor treatment had a mortality rate of 24.5%, while the rates for patients ...